Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Radiofrequency, chemotherapy prove effective duo in destroying tumors

20.06.2003


New study presented today at Image-guided Therapies media briefing



Radiofrequency ablation (RFA) combined with chemotherapy is currently being used to treat malignant liver tumors at a Boston hospital on the basis of results from a new study appearing in the July issue of the journal Radiology. The minimally invasive, outpatient procedure is performed on primary liver cancer or colon cancer tumors that have spread to the liver of patients at Beth Israel Deaconess Medical Center.

"It’s exciting that a simple, image-guided technique, along with chemotherapy, can enhance the area of tumor killed," said Jonathan B. Kruskal, M.D., Ph.D., section chief of abdominal imaging at Beth Israel Deaconess and associate professor of radiology at Harvard Medical School in Boston. "Our research shows that we are now able to treat larger tumors with this combined therapy."


RFA uses heat to destroy malignant tumors. After sedating the patient, radiologists locate the tumor with computed tomography (CT) or magnetic resonance (MR) imaging. A four- to 10-inch-long electrode, similar to a biopsy needle, is guided into the center of a tumor via imaging.

The electrode delivers radiofrequency current to heat and destroy the tumor tissue.

Dr. Kruskal co-authored the Radiology study, which indicated that with the addition of chemotherapy, tumors larger than five centimeters can be treated with RFA and that partially destroying tumors with RFA slows tumor growth and improves survival.

"Large tumors are typically not considered amenable to RFA treatment. Our results suggest that they may well be," he said.

The research, performed by Guiseppe D’Ippolito, M.D., and colleagues under the direction of S. Nahum Goldberg, M.D., the senior author of the study, was the first randomized controlled study on combined RFA and chemotherapy treatments in animals. Dr. Kruskal presented it today during a Radiological Society of North America (RSNA) media briefing on image-guided therapies.

Liposomal doxorubicin (a chemotherapeutic agent) and RFA were used to treat breast tumors implanted into 49 rats and grown from 10 days to two weeks. The animals were divided into four treatment groups: RFA only, doxorubicin only, RFA combined with doxorubicin, and a control group receiving no treatment.

Doxorubicin is dispensed in fat droplets, which circulate through the body and find the tumor, helping to destroy it. When doxorubicin was combined with RFA, results showed a reduction in tumor growth rates and a tripling in the average survival rate compared with the group receiving no treatment.

"The survival of animals increased from nine days in the control group to 27 days with the combined therapy," Dr. Kruskal said. "This study opens up the possibilities of using other drug cocktails with RFA to kill tumors and to treat tumors outside of the liver." RFA is a good option for treating liver tumors. Many people with liver tumors are not appropriate candidates for surgery because their tumors are too widespread or inaccessible or because of their poor physical health. They also may not be candidates for a liver transplant.

A liver tumor can be ablated with radiofrequency in about 30 to 60 minutes, without affecting the liver’s normal tissue. RFA is a one- to three-hour outpatient procedure that can be used to treat recurrent liver tumors. It is less risky than surgery, can be performed without general anesthesia and causes minimal discomfort. Patients can most often go home the same day.

Risks associated with RFA include bleeding and injury to other organs and "post-ablation" syndrome, which includes flu-like symptoms.

Beth Israel Deaconess is currently the only hospital providing combined RFA and liposomal chemotherapy, according to Dr. Kruskal. Approximately 25 patients have been treated with the combined therapy by Dr. Goldberg, director of the tumor ablation program at Beth Israel Deaconess, and they are seeing a 25 percent increase in the volume of tumor destruction. Based on these results, Drs. Goldberg and Kruskal are planning further studies, including a large clinical study comparing RFA alone to RFA combined with liposomal chemotherapy.

"RFA has been used worldwide for the last five or six years to treat tumors up to five centimeters," Dr. Kruskal said. "With the new combined therapy, where patients are given doxorubicin intravenously prior to the start of RFA, physicians will be able to treat larger tumors, up to eight centimeters."

The purpose of this study, partly funded by the National Cancer Institute and the National Institutes of Health, was to determine whether combined intravenous liposomal doxorubicin and RFA decreased tumor growth and increased endpoint survival – that is, from the start of treatment until the tumor reached three centimeters.

Following treatment, tumors were measured every two to three days until they reached three centimeters. The rats that received RFA and doxorubicin had a mean endpoint survival of 27 days. Rats receiving either RFA or injections of doxorubicin had an endpoint survival of 16 days. The control group, with no treatment, reached endpoint survival at 10 days.

Maureen Morley | EurekAlert!
Further information:
http://radiology.rsnajnls.org
http://www.RadiologyInfo.org.

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>